Celgene's Abraxane meets main goal in melanoma trial

Celgene Corp said on Tuesday that in a late-stage clinical trial, patients with metastatic melanoma who took its drug Abraxane lived for a longer period without getting worse than those who received the chemotherapy dacarbazine.

Share